PCA
SRPT icon

Private Capital Advisors’s Sarepta Therapeutics SRPT Stock Holding History

Private Capital Advisors’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-3,100
Closed -$241K – 106
2021
Q2 		$241K Buy
+3,100
New +$235K 0.04% 85
2017
Q3 		– Sell
-17,771
Closed -$599K – 121
2017
Q2 		$599K Buy
+17,771
New +$579K 0.19% 87

Other funds holding SRPT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Private Capital Advisors's SRPT Position: Q3 2021 in Review

Private Capital Advisors sold out of Sarepta Therapeutics (SRPT) in Q3 2021, closing a stake of 3,100 shares — an estimated $241K sold.

Private Capital Advisors first reported a position in SRPT in Q2 2017 and held it in 2 quarters. The position peaked at $599K in Q2 2017. 306 funds tracked by Wall St. Rank hold SRPT as of Q3 2021.

  • Private Capital Advisors reported no remaining Sarepta Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Private Capital Advisors sold 3,100 Sarepta Therapeutics shares in Q3 2021, an estimated $241K.
  • Private Capital Advisors first reported a position in Sarepta Therapeutics in Q2 2017 and held it in 2 quarters.
  • Private Capital Advisors's Sarepta Therapeutics position peaked at $599K in Q2 2017.
  • 306 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2021.

Based on Private Capital Advisors's 13F filing for Q3 2021, filed 12 Oct 2021.